Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel

被引:60
作者
Nitadori, JI
Ishii, G
Tsuta, K
Yokose, T
Murata, Y
Kodama, T
Nagai, K
Kato, H
Ochiai, A
机构
[1] Natl Canc Ctr, Res Inst E, Div Pathol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp, Thorac Oncol Div, Chiba, Japan
[3] Natl Canc Ctr Hosp, Dept Resp Oncol, Chiba, Japan
[4] Tokyo Med Univ, Dept Surg, Tokyo, Japan
关键词
lung cancer; large cell neuroendocrine carcinoma; small cell carcinoma; tissue microarray; immunohistochemistry; large antibody panel;
D O I
10.1309/DT6BJ698LDX2NGGX
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
To elucidate additional phenotypic differences between large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC), we performed tissue microarray (TMA) analysis of surgically resected LCNEC and SCLC specimens. Immunostaining with 48 antibodies was scored based on staining intensity and the percentage of cells that stained positively. Four proteins were identified as significantly expressed in LCNEC as compared with SCLC: cytokeratin (CK)7, 113 vs 49 (P < .0301); CK18, 171 vs 60 (P < .0008); E-cadherin, 77 vs 9 (P < .0073); and beta-catenin, 191 vs 120 (P < .0286). Immunostaining of cross-sections containing LCNEC and SCLC components revealed significant expression of CK7, CK18, and beta-catenin in the LCNEC component compared with the SCLC component in 2 of 3 cases. Our results indicate that significant expression of CK7, CK18, E-cadherin, and beta-catenin is more characteristic of LCNEC than of SCLC and these findings provide further support that these tumor types are separate entities morphologically and immunophenotypically, if not biologically.
引用
收藏
页码:682 / 692
页数:11
相关论文
共 24 条
[1]  
BROERS JLV, 1988, CANCER RES, V48, P3221
[2]   Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens [J].
Chhieng, DC ;
Cangiarella, JF ;
Zakowski, MF ;
Goswami, S ;
Cohen, JM ;
Yee, HT .
CANCER CYTOPATHOLOGY, 2001, 93 (05) :330-336
[3]   Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours [J].
Clavel, CE ;
Nollet, F ;
Berx, G ;
Tejpar, S ;
Naworcki-Raby, B ;
Kaplan, HH ;
van Roy, FM ;
Birembaut, PL .
JOURNAL OF PATHOLOGY, 2001, 194 (01) :20-26
[4]  
Demetri G, 1996, Oncology (Williston Park), V10, P179
[5]   Pulmonary large-cell neuroendocrine carcinoma (LCNEC) [J].
Hage, R ;
Seldenrijk, K ;
de Bruin, P ;
van Swieten, H ;
van den Bosch, J .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 23 (04) :457-460
[6]   USE OF AVIDIN-BIOTIN-PEROXIDASE COMPLEX (ABC) IN IMMUNOPEROXIDASE TECHNIQUES - A COMPARISON BETWEEN ABC AND UNLABELED ANTIBODY (PAP) PROCEDURES [J].
HSU, SM ;
RAINE, L ;
FANGER, H .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (04) :577-580
[7]  
Iyoda A, 2001, CANCER-AM CANCER SOC, V91, P1992, DOI 10.1002/1097-0142(20010601)91:11<1992::AID-CNCR1224>3.0.CO
[8]  
2-5
[9]   Tissue microarrays for high-throughput molecular profiling of tumor specimens [J].
Kononen, J ;
Bubendorf, L ;
Kallioniemi, A ;
Bärlund, M ;
Schraml, P ;
Leighton, S ;
Torhorst, J ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
NATURE MEDICINE, 1998, 4 (07) :844-847
[10]   Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas [J].
Lyda, MH ;
Weiss, LM .
HUMAN PATHOLOGY, 2000, 31 (08) :980-987